Modern therapy for inflammatory bowel disease

Scandinavian Journal of Gastroenterology, Supplement

Volumn 38, Issue 237, 2003, Pages 30-33

  Rutgeerts, P ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Biological therapy; Crohn disease; Ulcerative colitis

Indexed keywords

AMINOSALICYLIC ACID; AZATHIOPRINE; BUDESONIDE; CYCLOSPORIN; GLUCOCORTICOID; IMMUNOGLOBULIN 4 ANTIBODY; IMMUNOGLOBULIN ANTIBODY; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 11; METHOTREXATE; NATALIZUMAB; PROBIOTIC AGENT; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

CLINICAL TRIAL; CONFERENCE PAPER; CROHN DISEASE; DISEASE CONTROL; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; ENTERITIS; ENVIRONMENTAL FACTOR; GENETIC IDENTIFICATION; GENETIC SUSCEPTIBILITY; HEALING; HOST PATHOGEN INTERACTION; HUMAN; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE FLORA; INTESTINE MUCOSA; LONG TERM CARE; MAINTENANCE THERAPY; PATHOGENESIS; PATHOPHYSIOLOGY; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION; SEROLOGY; SIDE EFFECT; TREATMENT OUTCOME; ULCERATIVE COLITIS; ALGORITHM; BIOLOGICAL THERAPY; REVIEW;

ALGORITHMS; ANTIBODIES, MONOCLONAL; BIOLOGICAL THERAPY; COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES;

EID: 0038288007     PISSN: 00855928     EISSN: None     Source Type: Journal    
DOI: 10.1080/00855910310001467     Document Type: Conference Paper

References (18)

1. Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994;35:360-2.
2. Faubion WA, Jr, Loftus EV, Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. A population-based estimate of corticosteroid dependence and resistance in ulcerative colitis. Gastroenterology 2001;120 Suppl 1:755.
3. Colpaert S, Vanstraelen K, Liu Z, Penninckx F, Geboes K, Rugeerts P, et al. Decreased lamina propria effector cell responsiveness to interleukin-10 in ileal Crohn's disease. Clin Immunol 2002;102:68-76.
4. Sartor RS. Intestinal microflora in human and experimental IBD. Curr Opin GE 2001;17:324-30.
5. Hanauer SB, Lichtenstein GR, Colombel JF, et al. Maintenance Infliximab (Remicade) is safe, effective and steroid-sparing in Crohn's disease: preliminary results from the Accent I trial. Gastroenterology 2001;120 Suppl 1:99.
6. The Antegren Publication Committee. A randomised, double-blind, placebo-controlled, Pan-European study of a recombinant humanised antibody to α4 Integrin (Antegren) in moderate to severely active Crohn's disease. Gastroenterology 2001; 120 Suppl 1:682.
7. D'haens G, Van Deventer S, Van Hogezand R, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 1999;116:1029-34.
8. Noman M, Baert F, D'Haens G, et al. HACA formation after infliximab (Remicade) treatment in Crohn's disease is clearly associated with infusion reactions. Gastroenterology 2001;120 Suppl 1:3150.
9. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001;411:599-603.
10. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001;411:603-6.
11. Madsen K, Cornish A, Soper P, McKaigney C, Jijon H, Yachmimec C, et al. Probiotic bacteria enhance murine and human intestinal barrier function. Gastroenterology 2001;121:580-91.
12. Shanahan F. Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics. Gastroenterology 2001;120:622-35.
13. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999;354:635-9.
14. Kruis W, Schutz E, Fric P, Fixa B, Judmaier G, Stolte M. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997;11:853-8.
15. Venturi A, Gionchetti P, Rizzello F, et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999;13:1103-8.
16. Gionchetti P, Rizzello F, Venturia A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000;119:305-9.
17. Malchow HA. Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease? J Clin Gastroenterol 1997;25:653-8.
18. Guslandi M, Mezzi G, Sorghi M, Testoni PA. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 2000;45:1462-4.